News: Medicine

View:

2010

 

Found press releases

 

Number of outstanding shares in Elekta AB (publ)

12/30/2010 12:00 PM EST  -   Elekta
Press Release
Stockholm, Sweden, December 30, 2010
During December, 49,335 new B shares were issued in Elekta through the exercise of warrants distributed within the framework of the established option program.

The total number of shares in Elekta as of December 30, 2010 amounts to 94,188,044 divided between 3,562,500 A shares and 90,625,544 B shares.

One A share entitles the holder to ten votes and one...

Meda strengthens allergy product portfolio in Europe with EpiPen® Auto-Injector

12/23/2010 2:45 AM EST  -   MEDA
Meda has signed a long-term license agreement with the specialty division of Mylan Inc. (Nasdaq: MYL), Dey Pharma, L.P., for exclusive marketing and distribution rights of EpiPen® (epinephrine) Auto-Injector in Europe. EpiPen is used for emergency treatment of severe allergic reactions (anaphylaxis). Anaphylaxis can occur quickly (often within a couple of minutes) and may be life-threatening.

EpiPen is a...

Meda files complaint against 3M and claims damages

12/23/2010 2:00 AM EST  -   MEDA
Meda has filed a complaint against 3M and claims damages for breach of agreement in connection with Meda’s acquisition of 3M’s European pharmaceutical division in 2007. Meda’s claims are based upon 3M’s failure to disclose an essential agreement that it had entered into with the French authorities regarding the sale of Tambocor in France. This undisclosed agreement forced Meda, after the acquisition, to concede to...

PatLog in clinical use at the University of Mannheim, Germany

12/22/2010 6:33 AM EST  -   ONCOlog Medical
ONCOlog Medical QA AB and the Department of Radiation Oncology at University Medical Center Mannheim have signed a Research and an Evaluation Program about the use of PatLog© system from ONCOlog Medical in the daily treatment of radiotherapy patients with the Elekta Synergy© linac.
The PatLog© system consists of unique tools for immobilization of radiotherapy patients on the treatment table plate with a...

KARO BIO’S RIGHTS ISSUE FULLY SUBSCRIBED

12/22/2010 2:30 AM EST  -   Karo Bio
Stockholm, December 22, 2010 – Karo Bio AB’s (publ) (Reuters: KARO.ST) rights issue of approximately SEK 325 million was fully subscribed. A total of 228,361,055 shares, corresponding to 98.3 percent of the new shares, were subscribed for through the exercise of subscription rights.  Subscriptions for an additional 103,288,239 shares without the exercise of subscription rights, corresponding to 44 percent of the...

Notification of trade among insiders

12/17/2010 8:43 AM EST  -   DiaGenic ASA
On 17 December 2010 mandatory notification of trade among insiders of DiaGenic ASA took place.

Henrik Lund, Chairman of the Board of DiaGenic ASA, has purchased 400,000 shares in DiaGenic ASA at a price of NOK 0.97 per share. After the transaction, Lund holds 400,000 shares in the Company.

Ingrid Wiik, Vice Chairman of the Board of DiaGenic ASA, has purchased 200,000 shares in DiaGenic ASA at an average price...

DiaGenic and Pfizer to collaborate on blood based biomarkers for early stages of...

12/17/2010 2:40 AM EST  -   DiaGenic ASA
Oslo – December 17, 2010: DiaGenic ASA  [OSL:DIAG] and Pfizer Inc [NYSE: PFE] today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer’s disease (AD) using DiaGenic’s patented gene expression technology and its blood samples from ongoing clinical studies.
The companies will perform a joint modular study where they will compare longitudinal changes in blood...

Orexo and Boehringer Ingelheim report progress in their pain and inflammatory di...

12/16/2010 3:00 AM EST  -   Orexo
Uppsala/Sweden and Ingelheim/Germany, December 16, 2010 - Orexo AB (STO: ORX) and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in ...

Broncus Announces Release of LungPoint Planning and Virtual Bronchoscopic Naviga...

12/15/2010 9:13 AM EST  -   Broncus Technologies, Inc
Imaging Software used in the Diagnosis and Treatment of Lung Cancer and Other Lung Diseases

 

Software Offers Unique Solution for Lung Fiducial Planning
December 15, 2010, MOUNTAIN VIEW, CA – Broncus Technologies, Inc., a medical device company focused on developing minimally-invasive innovations for lung diseases, announced release today of its LungPoint® System version 3.0.  LungPoint is a navigation...

Elekta signs agreement to sell stake in Motala Verkstad AB

12/15/2010 4:45 AM EST  -   Elekta
Press Release
Stockholm, Sweden, December 15, 2010

Elekta has signed an agreement to sell its 49 percent stake in Motala Verkstad AB. The buyer is Qeep Group.
Motala Verkstad supplies a subsystem of the Leksell Gamma Knife ® and is also responsible for coordinating transportation of subsystems to Elekta’s customers. In order to develop the business in Motala Verkstad, Elekta has been looking for a stable...